Analysts Set Expectations for IOVA Q1 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Investment analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Iovance Biotherapeutics in a note issued to investors on Tuesday, February 24th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn ($0.15) per share for the quarter. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.54) EPS and FY2027 earnings at ($0.28) EPS.

A number of other equities research analysts also recently weighed in on IOVA. Barclays lifted their target price on Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Wednesday. The Goldman Sachs Group reiterated a “sell” rating and issued a $2.00 price objective on shares of Iovance Biotherapeutics in a research note on Thursday, February 5th. Chardan Capital decreased their target price on shares of Iovance Biotherapeutics from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $10.00.

Iovance Biotherapeutics Trading Down 1.0%

NASDAQ:IOVA opened at $3.79 on Thursday. The stock has a 50 day simple moving average of $2.69 and a 200 day simple moving average of $2.42. The stock has a market cap of $1.56 billion, a P/E ratio of -3.38 and a beta of 0.76. Iovance Biotherapeutics has a 1-year low of $1.64 and a 1-year high of $5.64.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 148.41% and a negative return on equity of 54.54%. The firm had revenue of $86.77 million during the quarter, compared to the consensus estimate of $81.61 million.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vontobel Holding Ltd. bought a new stake in shares of Iovance Biotherapeutics during the third quarter worth about $26,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Iovance Biotherapeutics during the 3rd quarter worth approximately $27,000. Arcataur Capital Management LLC acquired a new stake in Iovance Biotherapeutics during the 4th quarter worth approximately $29,000. Granite Investment Partners LLC bought a new stake in Iovance Biotherapeutics during the 4th quarter worth approximately $29,000. Finally, Motley Fool Asset Management LLC bought a new stake in Iovance Biotherapeutics during the 4th quarter worth approximately $29,000. Institutional investors own 77.03% of the company’s stock.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Reported strong Q4 and FY2025 results: 61% year‑over‑year revenue growth to $264M and Q4 product revenue of roughly $87M; Q4 EPS loss was narrower than expected and revenue beat consensus — this underpins the recent rally. Iovance Biotherapeutics (IOVA) Reports 61% Annual Revenue Growth Driven by Amtagvi Success
• Positive Sentiment: Amtagvi (lifileucel) is now an approved commercial product with accelerating adoption — company reported product sales growth (sales up ~30–33% in Q4) and lifileucel has received Fast Track designation in second‑line NSCLC; management plans registrational sarcoma studies after strong early responses. This shifts Iovance toward execution and revenue growth rather than a pure pipeline bet. Iovance FDA Approval Shifts Lifileucel From Pipeline Bet To Execution Test
• Positive Sentiment: Encouraging sarcoma data and 50% ORR in early cohorts prompted plans for a registrational sarcoma trial — clinical validation of TIL therapy in new indications supports upside to revenue and long‑term value. Iovance Announces Positive Results for TIL in Soft Tissue Sarcomas
• Positive Sentiment: Analysts updated models and ratings after the print — Barclays raised its target and kept an overweight stance; HC Wainwright raised FY2026/27 estimates and maintains a Buy with a higher target, and other firms issued buy/outperform notes — analyst support likely amplified buying. Analyst Coverage Changes
• Positive Sentiment: Operational story: coverage highlighting the Philadelphia manufacturing/scale‑up helps explain the stock’s multi‑week surge — investors are pricing in improved capacity to supply Amtagvi. Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why
• Neutral Sentiment: Management scheduled investor presentations at TD Cowen and Barclays conferences in early March — useful for more detail but not immediate catalysts. Iovance to Present at Upcoming Conferences
• Neutral Sentiment: Unusually large options volume and heavy intraday trading indicate speculative positioning and rapid repricing; this raises liquidity but not a directional fundamental change. Options Volume Report
• Negative Sentiment: Short interest ballooned (~36.9% of float, short‑interest ratio ~14.6 days) — while this can fuel squeezes on rallies, it also increases downside pressure and volatility when momentum fades or profit taking occurs.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.